Ketamine Therapy for Anxiety in Scottsdale

Generalized anxiety disorder, social anxiety disorder, and anxiety that co-occurs with depression are all conditions in which standard treatments can fall short. SSRIs and SNRIs are commonly prescribed and helpful for many patients — but for others, they produce only partial reduction in symptoms, or generate side effects that limit their usefulness.

Benzodiazepines are effective for short-term anxiety relief but carry significant risks of dependence, cognitive blunting, and rebound anxiety on discontinuation. They are not a long-term solution for most patients with chronic anxiety, and they do nothing to address the underlying neural patterns that sustain anxious thinking and behavior.

Ketamine offers a mechanistically distinct option. It acts on the glutamate system rather than the GABA or serotonin systems, and it promotes neuroplasticity — the brain's ability to form new connections and break out of rigid, established patterns. For patients whose anxiety has become entrenched and self-reinforcing, this is a meaningful distinction.

Unlike benzodiazepines, ketamine is not primarily a sedative and does not carry the same dependence risk. It does not work by simply damping down the nervous system. Instead, it acts on NMDA glutamate receptors, triggering a cascade that includes increased BDNF production and synaptogenesis — the formation of new synaptic connections.

The clinical significance of this is twofold. First, ketamine can produce rapid reductions in anxiety symptoms — often within hours of an infusion, rather than the weeks required for SSRI effects to accumulate. Second, the neuroplasticity that ketamine promotes creates a window during which patients are often more receptive to behavioral change and cognitive restructuring.

This is why integration support is a meaningful part of the Innerbloom approach. The ketamine session itself is the biological intervention. What happens in the hours, days, and weeks following — how patients engage with therapy and build new patterns — shapes how lasting the benefit will be.

Anxiety alone — without co-occurring depression or PTSD — requires careful clinical evaluation before recommending ketamine. The evidence base for ketamine in pure anxiety disorders is less developed than for depression or PTSD, and not every patient presenting with anxiety will be a good candidate.

This is precisely why the physician intake matters. During your initial consultation with Dr. Zabel, he will evaluate your full clinical picture. For many patients, anxiety co-occurs with depression or PTSD, which strengthens the clinical rationale for ketamine therapy. If you are not an appropriate candidate, Dr. Zabel will tell you honestly and help point you toward other options. If you are a candidate, the standard approach is an induction series of four to six IV ketamine infusions — see our pricing page for details.